BiotechTube

Lemborexant (LEM) 5 mg (Z-Drug-mono cohort) + Lemborexant (LEM) 5 mg (SUV-mono cohort) + Lemborexant (LEM) 5 mg (SUV-combination cohort) + Lemborexant (LEM) 5 mg (RMT-combination cohort)

ApprovedCompleted
0 watching 0 views this week🔥 Hot
85
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
✓
Phase 3
5
Approved
Indication / Disease

Insomnia

Conditions

Insomnia

Trial Timeline

Mar 24, 2021 → Jun 20, 2022

NCT ID
NCT04742699

About Lemborexant (LEM) 5 mg (Z-Drug-mono cohort) + Lemborexant (LEM) 5 mg (SUV-mono cohort) + Lemborexant (LEM) 5 mg (SUV-combination cohort) + Lemborexant (LEM) 5 mg (RMT-combination cohort)

Lemborexant (LEM) 5 mg (Z-Drug-mono cohort) + Lemborexant (LEM) 5 mg (SUV-mono cohort) + Lemborexant (LEM) 5 mg (SUV-combination cohort) + Lemborexant (LEM) 5 mg (RMT-combination cohort) is a approved stage product being developed by Eisai for Insomnia. The current trial status is completed. This product is registered under clinical trial identifier NCT04742699. Target conditions include Insomnia.

Hype Score Breakdown

Clinical
30
Activity
20
Company
10
Novelty
10
Community
12

Clinical Trials (1)

NCT IDPhaseStatus
NCT04742699ApprovedCompleted

Competing Products

20 competing products in Insomnia

See all competitors
ProductCompanyStageHype Score
ACT-541468 5 mg + ACT-541468 10 mg + ACT-541468 25 mg + Zolpidem + Placebo 1 + Placebo 2IdorsiaPhase 2
47
Zolpidem (Myslee®) + placeboAstellas PharmaApproved
85
zolpidemAstellas PharmaApproved
85
Mirtazapine TabletsSun PharmaceuticalApproved
85
E2006 1.0 mg + E2006 2.5 mg + E2006 5.0 mg + E2006 10.0 mg + E2006 25.0 mg + E2006 50.0 mg + E2006 100 mg + E2006 200 mg + Zolpidem 10 mg + E2006 Matched Placebo or Zolpidem Matched Placebo + E2006 Matched PlaceboEisaiPhase 1
33
Lemborexant 5 mg + Lemborexant 10 mg + Lemborexant-matched placebo. + Flurazepam 30 mgEisaiPhase 1
33
E2006EisaiPhase 1
33
Lemborexant + Lemborexant + Lemborexant-matched placebo + Zolpidem tartrate + Zolpidem-matched placeboEisaiPhase 3
77
LEM 5 mg + LEM 10 mgEisaiPhase 3
77
EszopicloneEisaiPre-clinical
23
Eszopiclone 1 mg + Eszopiclone 2 mg + Eszopiclone 3 mg + Placebo + Zolpidem Tartrate 10 mgEisaiPhase 2/3
65
lemborexant + PlaceboEisaiPhase 3
77
E2006 + PlaceboEisaiPhase 2
52
Zolpidem tablets + Suvorexant tablets, over-encapsulated + Lemborexant tablets + Placebo lemborexant + Placebo zolpidem + Placebo suvorexantEisaiPhase 1
33
EszopicloneEisaiPre-clinical
23
Eszopiclone 1 mg- Elderly + Eszopiclone 2 mg- Elderly + Eszopiclone 3 mg- Non-elderly + Eszopiclone 2 mg- Non-elderlyEisaiPhase 3
77
Eszopiclone 3 mg + Eszopiclone 1 mgEisaiPhase 1
33
LY2624803Eli LillyPhase 1
33
LY2624803 - Capsules + Zolpidem - Tablets + Placebo - Capsules + Placebo - TabletsEli LillyPhase 1
33
LY2624803Eli LillyPhase 1
33

Other Products from Eisai

MecobalaminApproved
85
MonteplaseApproved
85
E2020 + PlaceboApproved
85
Palonosetron 0.075 mg IV + Dexamethasone 10 mg IV + Promethazine 25 mg IVApproved
85
DonepezilApproved
85